A pooled analysis of 2310 HER2-negative breast cancer patients from four prospective neoadjuvant clinical trials showed that 34% of patients in the HoR-negative subgroup had HER2-low breast cancer, consistent with our study results (18). The gene discussed is ERBB2; the disease is breast cancer.